Also adding to this these approaches in preclinical and clinical studies have shown good efficacy in advanced HER2-positive/HER2-negative and triple-negative breast cancer with less tumor burden and severe organ complications. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.